Generics (paroxetine), or the new unbearable lightness of patents in competition law
Sign Up to like & getrecommendations! Published in 2021 at "European Competition Journal"
DOI: 10.1080/17441056.2021.1916212
Abstract: ABSTRACT Generics represents the first instance in which the CJEU analysed the contentious pay-for-delay cases. The Court had to take position on the interplay between IPRs and competition law as well as on potential competition,… read more here.
Keywords: law; generics paroxetine; law assessment; paroxetine new ... See more keywords
Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Law and the Biosciences"
DOI: 10.1093/jlb/lsac001
Abstract: Abstract Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for… read more here.
Keywords: competition law; competition; biologic drugs; case ... See more keywords
Has the time come to federalize private competition law? The autonomous concept of undertaking in the CJEU's ruling in Case C-724/17 Vantaa v. Skanska: Case C-724/17 Vantaan kaupunki v. Skanska Industrial Solutions Oy and Others, EU:C:2019:204
Sign Up to like & getrecommendations! Published in 2019 at "Maastricht Journal of European and Comparative Law"
DOI: 10.1177/1023263x19875354
Abstract: The private enforcement of EU competition law has been in the center of scholarly discourse for almost two decades. Recently, the CJEU, with its ruling adopted in Vantaa v. Skanska and others, opened a new… read more here.
Keywords: cjeu ruling; law; case 724; competition law ... See more keywords